LAWRENCE ARTHUR LOEB
Medical Practice in Seattle, WA
License number
Pennsylvania MD009956E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
2
Seattle, WA 98195
Pennsylvania
Pennsylvania
Personal information
See more information about LAWRENCE ARTHUR LOEB at radaris.comName
Address
Phone
13808 NE 36Th Pl, Bellevue, WA 98005
13808 NE 36Th Pl, Bellevue, WA 98005
13808 36Th Pl, Bellevue, WA 98005
Professional information
Dr. Lawrence A Loeb, Seattle WA - MD (Doctor of Medicine)
Specialties:
Other, Anatomic & Clinical Pathology
Address:
University Of Washington
1959 NE Pacific St, Seattle 98195
(206) 598-3300 (Phone), (206) 667-6643 (Fax)
UNIVERSITY OF WASHINGTON
1959 NE Pacific St, Seattle 98195
(206) 598-5637 (Phone), (206) 598-4303 (Fax)
UNIVERSITY OF WASHINGTON
1959 NE Pacific St, Seattle 98195
(206) 598-3300 (Phone), (206) 667-6643 (Fax)
1959 NE Pacific St, Seattle 98195
(206) 598-3300 (Phone), (206) 667-6643 (Fax)
UNIVERSITY OF WASHINGTON
1959 NE Pacific St, Seattle 98195
(206) 598-5637 (Phone), (206) 598-4303 (Fax)
UNIVERSITY OF WASHINGTON
1959 NE Pacific St, Seattle 98195
(206) 598-3300 (Phone), (206) 667-6643 (Fax)
Languages:
English
Education:
Medical School
New York Univ Sch Of Med
Graduated: 1961
New York Univ Sch Of Med
Graduated: 1961
Thermostable Polymerases Having Altered Fidelity And Methods Of Identifying And Using Same
US Patent:
2009000, Jan 1, 2009
Filed:
Dec 20, 2007
Appl. No.:
11/962067
Inventors:
Lawrence A. Loeb - Seattle WA, US
Leroy Hood - Seattle WA, US
Motoshi Suzuki - Nogoya, JP
Leroy Hood - Seattle WA, US
Motoshi Suzuki - Nogoya, JP
Assignee:
THE UNIVERSITY OF WASHINGTON - Seattle WA
International Classification:
C12Q 1/68, C12Q 1/48, C12N 9/10, C12N 15/11, C12P 19/34
US Classification:
435 6, 435 15, 435193, 536 232, 435 912
Abstract:
The present invention provides a method for identifying a thermostable polymerase having altered fidelity. The method consists of generating a random population of polymerase mutants by mutating at least one amino acid residue of a thermostable polymerase and screening the population for one or more active polymerase mutants by genetic selection. For example, the invention provides a method for identifying a thermostable polymerase having altered fidelity by mutating at least one amino acid residue in an active site O-helix of a thermostable polymerase. The invention also provides thermostable polymerases and nucleic acids encoding thermostable polymerases having altered fidelity, for example, high fidelity polymerases and low fidelity polymerases. The invention additionally provides a method for identifying one or more mutations in a gene by amplifying the gene with a high fidelity polymerase. The invention further provides a method for accurately copying repetitive nucleotide sequences using a high fidelity polymerase mutant. The invention also provides a method for diagnosing a genetic disease using a high fidelity polymerase mutant. The invention further provides a method for randomly mutagenizing a gene by amplifying the gene using a low fidelity polymerase mutant.
Oligonucleotide Probe Retrieval Assay For Dna Transactions In Mammalian Cells
US Patent:
2013011, May 9, 2013
Filed:
Oct 15, 2012
Appl. No.:
13/652431
Inventors:
Lawrence Loeb - Seattle WA, US
Edward J. Fox - Seattle WA, US
Edward J. Fox - Seattle WA, US
International Classification:
C12Q 1/68
US Classification:
435 611
Abstract:
Methods to measure a variety of DNA synthetic processes in live human cells by introducing and retrieving exogenous DNA probes are provided herein. Using fragments of bacterial plasmid or phage DNA, a wide array of DNA constructs may be assembled to mimic the intermediates of DNA transactions, including replication, translation synthesis, and end-joining. These DNA probes may be transfected into human cells and retrieved for mutational analysis using a modified Random Mutation Capture assay or NextGen DNA sequencing. These assays require only a small number of cells, such as might be available from biopsy material. Thus, the methods described herein may be applied to the early detection of cancer, predicting the responsiveness of individual cancers to chemotherapy, and measuring the DNA repair capacity of individuals to environmental DNA damaging agents. This approach may be automated and used for screening human populations for variations in DNA synthetic and repair activities.